Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
REGULATORY
Japan Selects JN.1 Substrains for COVID Vaccines in 2025-2026 Season
A Japanese health ministry panel on May 28 agreed to adopt “descendent lineages of the JN.1 strain” for the antigen composition of the COVID-19 vaccine to be used in the national immunization program in the 2025/2026 season. The decision was…
To read the full story
Related Article
- Japan Picks 5 COVID Vaccines for NIP Use from October
September 3, 2026
- Japan Selects JN.1 Substrains for COVID Vaccines in 2026-2027 Season
May 27, 2026
- Moderna Launches LP.8.1-Adapted Spikevax for Ages 6 Months to 11 Years
October 15, 2025
- Moderna Rolls Out LP.8.1-Tailored Spikevax in Japan
September 24, 2025
- Japan Panel Approves 5 COVID Vaccines for NIP Use from October
September 9, 2025
- Japan Approves Pfizer/BioNTech’s LP.8.1-Tailored COVID Vaccines
August 12, 2025
- Japan Approves Updated Spikevax for LP.8.1 Omicron Strain
August 6, 2025
- Moderna Japan Files Updated COVID Shot for Age 11 and Under
June 30, 2025
- LP.8.1-Adapted Novavax COVID Vaccine Filed in Japan: Takeda
June 30, 2025
- Moderna Files Updated Spikevax for LP.8.1 Strain in Japan
June 9, 2025
REGULATORY
- Public-Private Pharma Talks Expand to Domestic R&D, Manufacturing Investment
November 2, 2026
- Japan’s Healthcare Spending Hits Record 48.8 Trillion Yen in FY2024
November 2, 2026
- PMDA Renews Warning on Off-Label GLP-1 Use amid Adverse Event Reports
November 2, 2026
- PMDA Halts Medical Device Application Platform after Unauthorized Access
October 30, 2026
- Drug Makers Can Refuse Diabetes Drug Supply over Improper Prescribing: JFTC
October 30, 2026
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…